Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The U.S. Food and Drug Administration (FDA) has approved durvalumab in combination with etoposide and either carboplatin or cisplatin as a first-line treatment for patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC) based on the positive results of a randomized, multicenter, active-controlled, open-label trial (NCT03043872 - CASPIAN - Durvalumab + Tremelimumab + Carboplatin or Cisplatin + Etoposide vs Durvalumab + Carboplatin or Cisplatin + Etoposide vs Carboplatin or Cisplatin + Etoposide & Small-cell lung cancer (SCLC))
…